Results 151 to 160 of about 153,175,670 (281)

Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality

open access: yesBMEMat, EarlyView.
Nanotechnology offers a multi‐faceted approach to modern healthcare, encompassing high‐sensitivity diagnostic imaging, innovative vaccine delivery, and targeted therapeutics. This review explores how these nanomedicine applications address critical challenges in cancer recurrence and the treatment of neurologic and respiratory diseases to combat rising
Ahmed H. Ghonaim   +9 more
wiley   +1 more source

Hepatitis C and ageing: a community brief [PDF]

open access: yes, 2014
Executive summary: An estimated 226,700 people in Australia are living with chronic hepatitis C. While the numbers of people estimated to have been infected with hepatitis C has reduced over the past 15 years, the number of people with hepatitis C ...
Jacqui Richmond, Jack Wallace
core  

Multiscale Modeling of an 8‐Week Combination Regimen of Bemnifosbuvir and Ruzasvir in Patients with Chronic Hepatitis C Virus Infection

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Bemnifosbuvir (BEM) and ruzasvir (RZR) are pan‐genotypic HCV polymerase (NS5B) and NS5A inhibitors, respectively. In a single‐arm study (NCT05904470), 215 treatment‐naïve, adherent participants with chronic HCV (with or without cirrhosis) received BEM 550 mg QD plus RZR 180 mg QD for 8 weeks.
Carolin Zitzmann   +4 more
wiley   +1 more source

Prevalência dos marcadores das hepatites B e C em adolescentes de Blumenau [PDF]

open access: yes, 2012
Dissertação (mestrado) - Universidade Federal de Santa Catarina, Centro de Ciências de Saúde. Programa de Pós-Graduação em Farmácia, Florianópolis, 2009As infecções pelo vírus da hepatite B (HBV) e pelo vírus da hepatite C (HCV) são problemas mundiais de
Livramento, Andréa do
core  

Salivary gland B cell lymphoproliferative disorders in Sjögren's syndrome present a restricted use of antigen receptor gene segments similar to those used by hepatitis C virus‐associated non‐Hodgkins's lymphomas

open access: yesEuropean Journal of Immunology, 2002
V. De Re   +6 more
semanticscholar   +1 more source

A practical difference from the normal approach to evaluate natural killer (NK) cells and NK cell neoplasms by flow cytometry

open access: yesCytometry Part B: Clinical Cytometry, EarlyView.
Abstract Natural killer (NK) cell neoplasms span indolent to highly aggressive entities, and flow cytometric immunophenotyping is central to their detection and classification. However, distinguishing reactive from neoplastic NK cell expansions can be challenging because NK cells lack somatically recombined antigen receptors, and reactive states may ...
Aaron J. Wilk   +7 more
wiley   +1 more source

Prevalência dos marcadores das hepatites B e C em pacientes soropositivos para o HIV da região serrana do Estado de Santa Catarina [PDF]

open access: yes, 2009
Dissertação (mestrado) - Universidade Federal de Santa Catarina, Centro de Ciências de Saúde, Programa de Pós-Graduação em Farmácia, Florianópolis, 2009A presença do vírus da hepatite B (HBV) e da hepatite C (HCV) no portador do vírus da imunodeficiência
Souza, Ester Santos de
core  

Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection

open access: yesHepatology, 2010
A. Muir   +16 more
semanticscholar   +1 more source

Subset‐specific and tissue‐specific expression of NK‐cell markers and killer immunoglobulin‐like receptors: Implications for NK‐cell clonality assessment

open access: yesCytometry Part B: Clinical Cytometry, EarlyView.
Abstract Accurate immunophenotypic evaluation of natural killer (NK)‐cell neoplasms is challenging because NK‐cells lack somatically rearranged antigen receptors, are comprised of phenotypically distinct subsets, and exhibit tissue‐specific subset distribution. We developed a flow cytometry (FC) panel for NK‐cell immunophenotypic analysis and clonality
Valerie Woodings   +7 more
wiley   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy